Drug intelligence / Profile preview

T100

Development stage: Unknown
Lead developer: Tilray
Modality: Small Molecules
Administration: Oral

Overview

T100 is a pharmaceutical-grade medical cannabis oil drop product developed and manufactured by Tilray, a Canadian medical cannabis producer. It is intended for distribution to patients in markets such as Chile and Brazil, under physician supervision. As a medical cannabis product, its therapeutic effects are primarily mediated by various cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the body's endocannabinoid system.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on T100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T100.

Explore the full profile